Encyclopedia entry · research tier
GHK-Cu (research tier)
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-26
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · GHK-Cu (research tier)
GHK-Cu (glycyl-histidyl-lysine bound to copper) was discovered by Loren Pickart at the University of Washington in 1973 and has roughly 250 PubMed papers across five decades. The topical (cosmetic) form has the strongest human evidence base of any peptide on this site. The research-tier (injected or sublingual) form has zero published phase II or phase III human RCTs. Same molecule, two regulatory categories.
Looking for the cosmetic skincare framing? See GHK-Cu copper peptide for skincare.
Top UK GHK-Cu retailers
Mechanism of action
How GHK-Cu works
GHK-Cu is a copper-binding tripeptide. The proposed action is gene-expression modulation across roughly 4,000 genes per Pickart's 2018 review, including upregulation of decorin and downregulation of inflammatory cytokines, alongside direct support for collagen and glycosaminoglycan synthesis at the fibroblast level. The copper ion is integral to activity rather than incidental. Mechanism evidence is strong; systemic-human-translation evidence is not.
Research history
GHK-Cu has 50+ years of research literature, more than any other peptide on this site. Loren Pickart isolated the tripeptide from human plasma in 1973 while at the University of Washington and identified it as a factor promoting wound healing. Roughly 250 papers have followed, covering collagen synthesis, gene-expression modulation across approximately 4,000 genes, anti-inflammatory effects and antioxidant activity. Topical human studies dominate the clinical evidence base; systemic RCTs are absent.
- · Discovered by Loren Pickart at the University of Washington in 1973.
- · Originally identified as a factor in human plasma promoting wound healing.
- · Decades of in-vitro work covering collagen synthesis, gene expression modulation across approximately 4,000 genes, anti-inflammatory effects and antioxidant activity.
- · Topical human studies span skincare, scalp and hair follicle, and wound healing.
- · Systemic human RCT data is limited. Research-tier use claims rely heavily on extrapolation from in-vitro and topical studies.
Why two tiers exist for the same molecule
UK regulators distinguish between cosmetic claims (skincare, topical, no medicinal claim) and medicinal claims (systemic effects, healing, therapeutic claims). The same molecule can be lawful in tier one (cosmetic) and unlicensed-medicinal-product territory in tier two (research peptide with health claims). Sellers operating in tier two rely on "research use only, not for human consumption" framing to avoid the medicinal-product trigger.
This split is why the same molecule gets covered twice on PeptideClear. Different audience, different regulatory framing.
UK regulatory status (research tier)
- · Not controlled under the Misuse of Drugs Act 1971.
- · No UK marketing authorisation as a medicine.
- · Sold by UK research-peptide retailers under "research use only" framing.
- · Not on the WADA prohibited list as of the 2026 list.
Risks and unknowns
What the literature does not yet show about GHK-Cu (research tier)
Known concerns
- No published human RCT data on systemic / injected administration.
- Copper overload risk is theoretical but real. Endogenous copper homeostasis is tightly regulated and chronic exogenous loading is unstudied.
- Purity of UK research-peptide supply varies. Stoichiometry of the copper-peptide complex differs between manufacturers.
- Cold-chain handling between manufacture and delivery is not standardised in the research-peptide market.
Open questions in the literature
- Optimal route of administration for systemic effects has never been formally studied in humans.
- Pharmacokinetics of the copper-bound peptide in humans (half-life, clearance, copper distribution) are not characterised.
- Long-term effects of chronic systemic GHK-Cu on hepatic copper levels and ceruloplasmin are unknown.
- Whether the proposed gene-expression effects translate from in vitro fibroblast culture to systemic human administration is unestablished.
Regulatory note
Not controlled under UK law. No UK marketing authorisation as a medicine. Sold legally as a research chemical when marketed without therapeutic claims. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Frequently asked questions
Is GHK-Cu legal in the UK?
What does the human evidence show for GHK-Cu?
What is the regulatory status of GHK-Cu?
What forms is GHK-Cu available in?
Where can I learn more about GHK-Cu?
Where to buy GHK-Cu in the UK
Side-by-side price comparison across UK research peptide retailers. Trust Index ranking. Research use only.
Compare UK retailersClinical evidence record
Read the clinical evidence record for GHK-Cu
Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.
Popular on PeptideClear
Ready to buy
Buy GHK-Cu in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.